Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Aripiprazole IM Depot in Chinese Schizophrenia
NCT03285503Phase 1Completed
- Sponsor
- Otsuka Holdings
- Start
- Aug 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aripiprazole in schizophrenia, sponsored by Otsuka Holdings. Primary endpoints: Maximum Plasma Concentration up to 24 weeks, Time of Maximum Observed Plasma Concentration up to 24 weeks and 2 more. Started Aug 2018; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03285503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285503.